
Nicholas C Grassly

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/510694/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Modelling the spread of serotype-2 vaccine derived-poliovirus outbreak in Pakistan and Afghanistan to inform outbreak control strategies in the context of the COVID-19 pandemic. Vaccine, 2023, 41, A93-A104.	3.8	7
2	Characterizing Environmental Surveillance Sites in Nigeria and Their Sensitivity to Detect Poliovirus and Other Enteroviruses. Journal of Infectious Diseases, 2022, 225, 1377-1386.	4.0	18
3	Time Taken to Detect and Respond to Polio Outbreaks in Africa and the Potential Impact of Direct Molecular Detection and Nanopore Sequencing. Journal of Infectious Diseases, 2022, 226, 453-462.	4.0	6
4	Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa. Lancet Infectious Diseases, The, 2022, 22, 284-294.	9.1	25
5	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates. Clinical Infectious Diseases, 2022, 75, e764-e773.	5.8	5
6	Reassessing Reported Deaths and Estimated Infection Attack Rate during the First 6 Months of the COVID-19 Epidemic, Delhi, India. Emerging Infectious Diseases, 2022, 28, 759-766.	4.3	3
7	Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study. Lancet, The, 2021, 397, 398-408.	13.7	144
8	Factors Predicting Blood Culture Positivity in Children With Enteric Fever. Journal of Infectious Diseases, 2021, 224, S484-S493.	4.0	4
9	<i>Salmonella</i> Typhi Shedding and Household Transmission by Children With Blood Culture-Confirmed Typhoid Fever in Vellore, South India. Journal of Infectious Diseases, 2021, 224, S593-S600.	4.0	9
10	Impact of maternal antibodies and microbiota development on the immunogenicity of oral rotavirus vaccine in African, Indian, and European infants. Nature Communications, 2021, 12, 7288.	12.8	26
11	The role of genetic sequencing and analysis in the polio eradication programme. Virus Evolution, 2020, 6, veaa040.	4.9	19
12	A pilot study on use of live attenuated rotavirus vaccine (Rotarixâ,,¢) as an infection challenge model. Vaccine, 2020, 38, 7357-7362.	3.8	7
13	Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study. Lancet Infectious Diseases, The, 2020, 20, 1381-1389.	9.1	171
14	Surveillance optimisation to detect poliovirus in the pre-eradication era: a modelling study of England and Wales. Epidemiology and Infection, 2020, 148, e157.	2.1	5
15	The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. Science, 2020, 369, 413-422.	12.6	718
16	Evolving epidemiology of poliovirus serotype 2 following withdrawal of the serotype 2 oral poliovirus vaccine. Science, 2020, 368, 401-405.	12.6	105
17	Rapid and Sensitive Direct Detection and Identification of Poliovirus from Stool and Environmental Surveillance Samples by Use of Nanopore Sequencing. Journal of Clinical Microbiology, 2020, 58, .	3.9	33
18	Immune predictors of oral poliovirus vaccine immunogenicity among infants in South India. Npj Vaccines, 2020, 5, 27.	6.0	3

#	Article	IF	CITATIONS
19	Vaccine schedules and the effect on humoral and intestinal immunity against poliovirus: a systematic review and network meta-analysis. Lancet Infectious Diseases, The, 2019, 19, 1121-1128.	9.1	26
20	Interventions to improve oral vaccine performance: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2019, 19, 203-214.	9.1	51
21	Influence of Nonpolio Enteroviruses and the Bacterial Gut Microbiota on Oral Poliovirus Vaccine Response: A Study from South India. Journal of Infectious Diseases, 2019, 219, 1178-1186.	4.0	34
22	FUT2 Secretor Status Is Not Associated With Oral Poliovirus Vaccine Immunogenicity in South Indian Infants. Journal of Infectious Diseases, 2019, 219, 578-581.	4.0	3
23	Routine immunization in Pakistan: comparison of multiple data sources and identification of factors associated with vaccination. International Health, 2018, 10, 84-91.	2.0	31
24	The seasonality of nonpolio enteroviruses in the United States: Patterns and drivers. Proceedings of the United States of America, 2018, 115, 3078-3083.	7.1	81
25	Causes of impaired oral vaccine efficacy in developing countries. Future Microbiology, 2018, 13, 97-118.	2.0	154
26	Quantity of Vaccine Poliovirus Shed Determines the Titer of the Serum Neutralizing Antibody Response in Indian Children Who Received Oral Vaccine. Journal of Infectious Diseases, 2018, 217, 1395-1398.	4.0	5
27	Population sensitivity of acute flaccid paralysis and environmental surveillance for serotype 1 poliovirus in Pakistan: an observational study. BMC Infectious Diseases, 2018, 18, 176.	2.9	17
28	Eradicating polio with a vaccine we must stop using. Lancet Infectious Diseases, The, 2018, 18, 590-591.	9.1	3
29	The effect of probiotics and zinc supplementation on the immune response to oral rotavirus vaccine: A randomized, factorial design, placebo-controlled study among Indian infants. Vaccine, 2018, 36, 273-279.	3.8	60
30	Influence of the intestinal microbiota on the immunogenicity of oral rotavirus vaccine given to infants in south India. Vaccine, 2018, 36, 264-272.	3.8	88
31	Securing the Eradication of All Polioviruses. Clinical Infectious Diseases, 2018, 67, S1-S3.	5.8	3
32	Effect of Inactivated Poliovirus Vaccine Campaigns, Pakistan, 2014–2017. Emerging Infectious Diseases, 2018, 24, 2113-2115.	4.3	7
33	Type 2 Poliovirus Detection after Global Withdrawal of Trivalent Oral Vaccine. New England Journal of Medicine, 2018, 379, 834-845.	27.0	59
34	Exploring the relationship between environmental enteric dysfunction and oral vaccine responses. Future Microbiology, 2018, 13, 1055-1070.	2.0	42
35	Serotype-specific immunity explains the incidence of diseases caused by human enteroviruses. Science, 2018, 361, 800-803.	12.6	87
36	Enhancing Rotavirus Vaccination: A Microbial Fix?. Cell Host and Microbe, 2018, 24, 195-196.	11.0	4

#	Article	IF	CITATIONS
37	Study design and baseline results of an open-label cluster randomized community-intervention trial to assess the effectiveness of a modified mass deworming program in reducing hookworm infection in a tribal population in southern India. Contemporary Clinical Trials Communications, 2017, 5, 49-55.	1.1	14
38	Impact of maternal antibodies and infant gut microbiota on the immunogenicity of rotavirus vaccines in African, Indian and European infants: protocol for a prospective cohort study. BMJ Open, 2017, 7, e016577.	1.9	21
39	Changes in the intestinal microbiota following the administration of azithromycin in a randomised placebo-controlled trial among infants in south India. Scientific Reports, 2017, 7, 9168.	3.3	55
40	An assessment of the geographical risks of wild and vaccine-derived poliomyelitis outbreaks in Africa and Asia. BMC Infectious Diseases, 2017, 17, 367.	2.9	17
41	Quantifying Transmission Heterogeneity Using Both Pathogen Phylogenies and Incidence Time Series. Molecular Biology and Evolution, 2017, 34, 2982-2995.	8.9	37
42	Estimated Effect of Inactivated Poliovirus Vaccine Campaigns, Nigeria and Pakistan, January 2014–April 2016. Emerging Infectious Diseases, 2017, 23, 258-263.	4.3	14
43	Risk factors and short-term projections for serotype-1 poliomyelitis incidence in Pakistan: A spatiotemporal analysis. PLoS Medicine, 2017, 14, e1002323.	8.4	19
44	Faster Detection of Poliomyelitis Outbreaks to Support Polio Eradication. Emerging Infectious Diseases, 2016, 22, 449-456.	4.3	18
45	The Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysis. PLoS Neglected Tropical Diseases, 2016, 10, e0004616.	3.0	134
46	The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomised controlled trial. Journal of Infectious Diseases, 2016, 215, jiw595.	4.0	12
47	Editorial Commentary: Pediatric Norovirus in Developing Countries: A Picture Slowly Comes Into Focus. Clinical Infectious Diseases, 2016, 62, 1218-1220.	5.8	7
48	Polio vaccination: preparing for a change of routine. Lancet, The, 2016, 388, 107-108.	13.7	5
49	The effect of azithromycin on the immunogenicity of oral poliovirus vaccine: a double-blind randomised placebo-controlled trial in seronegative Indian infants. Lancet Infectious Diseases, The, 2016, 16, 905-914.	9.1	55
50	Factors determining anti-poliovirus type 3 antibodies among orally immunised Indian infants. Vaccine, 2016, 34, 4979-4984.	3.8	6
51	Unravelling mucosal immunity to poliovirus. Lancet Infectious Diseases, The, 2016, 16, 1310-1311.	9.1	7
52	Population Immunity against Serotype-2 Poliomyelitis Leading up to the Global Withdrawal of the Oral Poliovirus Vaccine: Spatio-temporal Modelling of Surveillance Data. PLoS Medicine, 2016, 13, e1002140.	8.4	15
53	Spatial Dynamics and High Risk Transmission Pathways of Poliovirus in Nigeria 2001-2013. PLoS ONE, 2016, 11, e0163065.	2.5	4
54	Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame. PLoS Pathogens, 2016, 12, e1005728.	4.7	44

#	Article	IF	CITATIONS
55	Biological challenges to effective vaccines in the developing world. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140138.	4.0	23
56	Estimating the Future Impact of a Multi-Pronged Intervention Strategy on Ocular Disease Sequelae Caused by Trachoma: A Modeling Study. Ophthalmic Epidemiology, 2015, 22, 394-402.	1.7	11
57	The epidemiology of non-polio enteroviruses. Current Opinion in Infectious Diseases, 2015, 28, 479-487.	3.1	106
58	Antibiotic Resistance in <i>Streptococcus pneumoniae</i> after Azithromycin Distribution for Trachoma. Journal of Tropical Medicine, 2015, 2015, 1-8.	1.7	22
59	New vaccine strategies to finish polio eradication. Lancet Infectious Diseases, The, 2015, 15, 864-865.	9.1	2
60	Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. Expert Review of Vaccines, 2015, 14, 1113-1123.	4.4	51
61	A New Method for Estimating the Coverage of Mass Vaccination Campaigns Against Poliomyelitis From Surveillance Data. American Journal of Epidemiology, 2015, 182, 961-970.	3.4	9
62	Immunogenicity and Effectiveness of Routine Immunization With 1 or 2 Doses of Inactivated Poliovirus Vaccine: Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2014, 210, S439-S446.	4.0	56
63	The role of older children and adults in wild poliovirus transmission. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10604-10609.	7.1	44
64	Influence of Enteric Infections on Response to Oral Poliovirus Vaccine: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2014, 210, 853-864.	4.0	63
65	Genomic analysis of emerging pathogens: methods, application and future trends. Genome Biology, 2014, 15, 541.	8.8	23
66	Key issues in the persistence of poliomyelitis in Nigeria: a case-control study. The Lancet Global Health, 2014, 2, e90-e97.	6.3	40
67	Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet, The, 2014, 384, 1505-1512.	13.7	99
68	Efficacy of inactivated poliovirus vaccine in India. Science, 2014, 345, 922-925.	12.6	105
69	Integration, community engagement, and polio eradication in Nigeria – Authors' reply. The Lancet Global Health, 2014, 2, e316.	6.3	1
70	Contextâ€dependent amphibian host population response to an invading pathogen. Ecology, 2013, 94, 1795-1804.	3.2	64
71	The Potential Impact of Routine Immunization with Inactivated Poliovirus Vaccine on Wild-type or Vaccine-derived Poliovirus Outbreaks in a Posteradication Setting. American Journal of Epidemiology, 2013, 178, 1579-1587.	3.4	21
72	Using a Nonparametric Multilevel Latent Markov Model to Evaluate Diagnostics for Trachoma. American Journal of Epidemiology, 2013, 177, 913-922.	3.4	17

#	Article	IF	CITATIONS
73	The final stages of the global eradication of poliomyelitis. Philosophical Transactions of the Royal Society B: Biological Sciences, 2013, 368, 20120140.	4.0	63
74	Waning Intestinal Immunity After Vaccination With Oral Poliovirus Vaccines in India. Journal of Infectious Diseases, 2012, 205, 1554-1561.	4.0	66
75	Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge. PLoS Pathogens, 2012, 8, e1002599.	4.7	180
76	A Diagnostics Platform for the Integrated Mapping, Monitoring, and Surveillance of Neglected Tropical Diseases: Rationale and Target Product Profiles. PLoS Neglected Tropical Diseases, 2012, 6, e1746.	3.0	81
77	The effect of mass immunisation campaigns and new oral poliovirus vaccines on the incidence of poliomyelitis in Pakistan and Afghanistan, 2001–11: a retrospective analysis. Lancet, The, 2012, 380, 491-498.	13.7	53
78	Monitoring trends in HIV prevalence among young people, aged 15 to 24 years, in Manicaland, Zimbabwe. Journal of the International AIDS Society, 2011, 14, 27-27.	3.0	11
79	A Statistical Model of the International Spread of Wild Poliovirus in Africa Used to Predict and Prevent Outbreaks. PLoS Medicine, 2011, 8, e1001109.	8.4	29
80	Asymptomatic Wild‶ype Poliovirus Infection in India among Children with Previous Oral Poliovirus Vaccination. Journal of Infectious Diseases, 2010, 201, 1535-1543.	4.0	46
81	Targeting Antibiotics to Households for Trachoma Control. PLoS Neglected Tropical Diseases, 2010, 4, e862.	3.0	22
82	Implications of a Circulating Vaccine-Derived Poliovirus in Nigeria. New England Journal of Medicine, 2010, 362, 2360-2369.	27.0	126
83	Modelling Trachoma for Control Programmes. Advances in Experimental Medicine and Biology, 2010, 673, 141-156.	1.6	12
84	Estimating Household and Community Transmission of Ocular Chlamydia trachomatis. PLoS Neglected Tropical Diseases, 2009, 3, e401.	3.0	42
85	Expression Profiling the Temperature-Dependent Amphibian Response to Infection by Batrachochytrium dendrobatidis. PLoS ONE, 2009, 4, e8408.	2.5	135
86	Pandemic Potential of a Strain of Influenza A (H1N1): Early Findings. Science, 2009, 324, 1557-1561.	12.6	1,665
87	Mucosal Immunity after Vaccination with Monovalent and Trivalent Oral Poliovirus Vaccine in India. Journal of Infectious Diseases, 2009, 200, 794-801.	4.0	75
88	Response—Influenza. Science, 2009, 325, 1072-1073.	12.6	2
89	The Development of an Age-Structured Model for Trachoma Transmission Dynamics, Pathogenesis and Control. PLoS Neglected Tropical Diseases, 2009, 3, e462.	3.0	89
90	Mathematical models of infectious disease transmission. Nature Reviews Microbiology, 2008, 6, 477-487.	28.6	527

#	Article	IF	CITATIONS
91	Effectiveness of Immunization against Paralytic Poliomyelitis in Nigeria. New England Journal of Medicine, 2008, 359, 1666-1674.	27.0	62
92	Infectious Disease Surveillance. JAMA - Journal of the American Medical Association, 2008, 300, 1591.	7.4	1
93	The Natural History of Trachoma Infection and Disease in a Gambian Cohort with Frequent Follow-Up. PLoS Neglected Tropical Diseases, 2008, 2, e341.	3.0	82
94	Protective efficacy of a monovalent oral type 1 poliovirus vaccine: a case-control study. Lancet, The, 2007, 369, 1356-1362.	13.7	134
95	Protective efficacy of a monovalent oral type 1 poliovirus vaccine – Authors' reply. Lancet, The, 2007, 370, 129-130.	13.7	1
96	Trachoma: transmission, infection, and control. Lancet Infectious Diseases, The, 2007, 7, 420-427.	9.1	45
97	Seasonal infectious disease epidemiology. Proceedings of the Royal Society B: Biological Sciences, 2006, 273, 2541-2550.	2.6	409
98	Projecting the demographic impact of AIDS and the number of people in need of treatment: updates to the Spectrum projection package. Sexually Transmitted Infections, 2006, 82, iii45-iii50.	1.9	75
99	New Strategies for the Elimination of Polio from India. Science, 2006, 314, 1150-1153.	12.6	230
100	Methods to Estimate the Number of Orphans as a Result of AIDS and Other Causes in Sub-Saharan Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2005, 39, 365-375.	2.1	23
101	Host immunity and synchronized epidemics of syphilis across the United States. Nature, 2005, 433, 417-421.	27.8	215
102	The future of the HIV pandemic. Bulletin of the World Health Organization, 2005, 83, 378-82.	3.3	11
103	The UNAIDS Estimation and Projection Package: a software package to estimate and project national HIV epidemics. Sexually Transmitted Infections, 2004, 80, i5-i9.	1.9	116
104	Maximising the global use of HIV surveillance data through the development and sharing of analytical tools. Sexually Transmitted Infections, 2004, 80, i1-i4.	1.9	10
105	Uncertainty in estimates of HIV/AIDS: the estimation and application of plausibility bounds. Sexually Transmitted Infections, 2004, 80, i31-i38.	1.9	64
106	The workbook approach to making estimates and projecting future scenarios of HIV/AIDS in countries with low level and concentrated epidemics. Sexually Transmitted Infections, 2004, 80, i10-i13.	1.9	34
107	Comparison of household-survey estimates with projections of mortality and orphan numbers in sub-Saharan Africa in the era of HIV/AIDS. Population Studies, 2004, 58, 207-217.	2.1	24
108	Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic?. Lancet, The, 2004, 363, 2180-2185.	13.7	92

#	Article	IF	CITATIONS
109	Modelling emerging HIV epidemics: the role of injecting drug use and sexual transmission in the Russian Federation, China and India. International Journal of Drug Policy, 2003, 14, 25-43.	3.3	68
110	Explicit models make for better policy. International Journal of Drug Policy, 2003, 14, 339-341.	3.3	1
111	The economic impact of HIV/AIDS on the education sector in Zambia. Aids, 2003, 17, 1039-1044.	2.2	33
112	Back to basics in HIV prevention: focus on exposure. BMJ: British Medical Journal, 2003, 326, 1384-1387.	2.3	90
113	Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: Recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. Aids, 2002, 16, W1-W14.	2.2	107
114	Can we reverse the HIV/AIDS pandemic with an expanded response?. Lancet, The, 2002, 360, 73-77.	13.7	143
115	Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nature Medicine, 2002, 8, 651-654.	30.7	33
116	AIDS: the makings of a development disaster?. Journal of International Development, 2001, 13, 391-409.	1.8	12
117	The effectiveness of HIV prevention and the epidemiological context. Bulletin of the World Health Organization, 2001, 79, 1121-32.	3.3	41
118	Error, Population Structure and the Origin of Diverse Sign Systems. Journal of Theoretical Biology, 2000, 206, 369-378.	1.7	11
119	Population dynamics of HIV-1 inferred from gene sequences. Genetics, 1999, 151, 427-38.	2.9	47
120	Mortality among Human Immunodeficiency Virus Type 2-Positive Villagers in Rural Guinea-Bissau Is Correlated with Viral Genotype. Journal of Virology, 1998, 72, 7895-7899.	3.4	18
121	A likelihood method for the detection of selection and recombination using nucleotide sequences. Molecular Biology and Evolution, 1997, 14, 239-247.	8.9	167
122	Polio's detection in London is a wake-up call. BMJ, The, 0, , o1589.	6.0	2